11 October 2024
11 October 2024
Whilst the events do not outline any new safety risks, the data gives a new understanding of the link between oncogenesis and Skysona.
KeyBioscience is set to receive an initial payment, with potential downstream payments of up to $1.4bn.
The launch of the facility is aimed at meeting rising global demand for biosafety testing services.
Apollo Health Ventures and Novo Holdings spearheaded the financing round, raising $15m.
Eli Lilly and insitro said the deals offers a “new paradigm” for collaborations between major pharmaceutical companies and smaller biotechs.
At CPHI Europe, Angela Vollstedt, global director of Cell & Gene Therapies at Novartis discussed scale up strategies for cell therapies.
As a risk factor for future serious health conditions, the early prevention, detection and management of type 2 diabetes are essential.
The company plans to start a Phase III trial for felzartamab as a treatment for antibody-mediated rejection, and two other indications in 2025.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
